METHODS OF TREATING PREDIABETES OR REDUCING THE RISK OF DEVELOPING TYPE 2 DIABETES WITH DAPAGLIFLOZIN
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Apr 3, 2025
app pub date -
Jan 25, 2023
filing date -
Jan 25, 2023
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure is directed to methods of reducing the risk of developing Type 2 diabetes and/or treating prediabetes in a patient in need thereof, the method comprising administering to the patient, an effective amount of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, wherein the patient has an HbA1c between 5.7% to 6.4% and/or a fasting glucose between 100 to 125 mg/dl.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully